Default company panoramic image
Logo

PolyBatics

PolyBatics designs, develops, manufactures and markets bionanoparticles used in the production of therapeutic proteins.

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Palmerston North, Manawatu-Wanganui Region, New Zealand
  • Currency NZD
  • Founded January 2009
  • Employees 13
  • Website polybatics.com

Company Summary

PolyBatics has developed a technology to produce affinity chromatography media in a single step. We produce custom functional nanoparticles for the purification of nutriceuticals and drugs from complex solutions in a single step, as contrasted to three steps using current methods. We can reduce the cost of the harvest step by 82%. These materials are used by biotech, food and pharmaceutical companies worldwide. This is a platform technology.

Team

  • Default avatar
    Andy Herbert
    VP Product Development

    Andy has experience in developing processes for the manufacture of biotechnology and fine chemical products. He has managed a department of 50 people responsible for the development of new human vaccines. He has a detailed knowledge of technologies such as fermentation, cell culture, separation, purification and chemical synthesis. His knowledge has been applied to products such as recombinant proteins, vaccines, biologicals, enzymes and fine c

  • Default avatar
    Tracy Neal Thompson
    CEO

    Tracy has worked in senior capacities for seven start-ups including LifeScan (sold to Johnson and Johnson), BioTrak (sold to Roche) and Cholestech, recently acquired by Alear). He held senior management positions in the merger and acquisition business of the $1.7 billion life sciences division of Agilent Technologies (formerlY Hewlett-Packard) and GeneChip manufacturer, Affymetrix and has developed international sales and marketing organisations.

  • Default avatar
    Bernd Helmut Adam Rehm
    CSO

    Bernd is professor of microbiology at Massey University and the inventor of the PolyBatics technology. Bernd is the author of over 100 papers on biopolymer production and is named on more then 10 patents. He is a recognized world authority on biopolymer production and is an editorial board member on eight scientific journals

  • Default avatar
    Brad Duft
    Chairman

    Brad Duft is the President and CEO of CoDa Therapeutics, a New Zealand drug company. In addition to his role with CoDa, Brad is a US patent attorney and former general counsel at Amylin Therapeutics with experience in international patent and corporate law.

  • Default avatar
    Jim Mervis
    Director

    Jim is Charman of CoDa Therapeutics and a US attorney. Jim brings extensive experience in transactional and securities law. In addition to his role woth CoDa, Jim advises UniServices at Auckland University and is the founder of Barrier Therapeutics.

  • Default avatar
    Richard Garland
    Director

    Dr. Garlend is the former Managing Director of New Zealand Pharmaceuticals. Richard oversaw the management buyout of NZP and ran the organization for many years. He brings experience in international markets and manufacturing.

Advisors

  • Default avatar
    Simpson Grierson
    Lawyer
    Unconfirmed
    Default avatar
    About Time Accounting
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Manawatu Investor Group
    Unconfirmed
    Default avatar
    K One W One
    Unconfirmed
    Default avatar
    NZVIF
    Unconfirmed